Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009

China Aoxing Pharmaceutical Co., Inc.: China Aoxing Pharmaceutical Company Receives Renewal of GMP Certification for Capsule Do


//health-fitness.news-articles.net/content/2009/ .. renewal-of-gmp-certification-for-capsule-do.html
Published in Health and Fitness on Thursday, July 23rd 2009 at 5:12 GMT, Last Modified on 2009-07-23 05:12:46 by Market Wire   Print publication without navigation


NEW YORK, NY--(Marketwire - July 23, 2009) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it has received renewal of the Good Manufacturing Practice (GMP) certification for its capsule formulation and packaging production facility. The certificate of compliance has a five-year term and was issued by the State Food and Drug Administration (SFDA) following a site inspection.

"Good Manufacturing Practice" is a body of internationally accepted regulations set forth by drug agencies at many countries. GMP compliance ensures that pharmaceuticals, active ingredients and medical devices are produced and quality-controlled according to state-of-the-art standards. According to the National Medicine Administration Law of the People's Republic of China, all pharmaceutical manufacturers must pass an examination every five years to renew their GMP Certificates.

"GMP compliance is the gold standard in quality assurance in the life science industry. We are happy to obtain the renewal of the GMP certificate for capsule products," said Juan Yue Han, Chairman and the CEO of China Aoxing. "This provides the foundation for the further development of China Aoxing. We are well positioned to manufacture pharmaceutical products in capsule dosage form to address significantly unmet medical needs in the areas of cancer pain, acute and chronic pain, as well as other neurological disorders."

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: [ AOB ]) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


Publication Contributing Sources

Similar Health and Fitness Publications